CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1228)

VOLUNTARY ANNOUNCEMENT

ANNOUNCEMENT OF PRELIMINARY CLINICAL DATA OF PHASE 1B STUDY OF OMOPRUBART (CAN106) IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

This announcement is made by CANbridge Pharmaceuticals Inc. (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") hereby informs the shareholders and potential investors of the Company that preliminary clinical data of the ongoing Phase 1b study of Omoprubart (CAN106), a novel, long-acting, anti-Complement component 5 (C5) complement recombinant humanized monoclonal antibody, in paroxysmal nocturnal hemoglobinuria (PNH) in China has been announced.

In this 26-week, multicenter, open-label, dose ascending trial in 16 PNH patients who have not received complement-inhibitor treatment, Omoprubart was administered intravenously every four weeks at three different maintenance doses after a loading dose period. Data from the two lower dose cohorts was reviewed through 26 weeks, while data from the highest dose cohort was reviewed through 13 weeks, the latest timepoint. Omoprubart treatment resulted in rapid, dose-dependent reductions in lactate dehydrogenase (LDH) from baseline, with mean LDH reductions of 49% in Cohort 1, 73% in Cohort 2, and 81% in Cohort 3. The percentage of subjects reaching an LDH level less than 1.5 times the upper limit of normal, the therapeutic goal for hemolysis inhibition with an anti-C5 antibody, at least once during the study was 25% in Cohort 1, 50% in Cohort 2, and 88% in Cohort 3. Hemoglobin levels increased across all study cohorts, with mean increases from baseline of approximately 2 g/dL in Cohorts 1 and 2 at Week 26, and 1 g/dL in Cohort 3 at Week 13. All subjects in Cohort 1 have been treated with Omoprubart for over one year, with a mean hemoglobin increase of approximately 4 g/dL from baseline. Patients with PNH often require frequent blood transfusions to treat severe anemia due to hemolysis.

Omoprubart was safe and well-tolerated at all doses. All drug-related adverse events were mild or moderate and transient, and none led to discontinuation from the study. There were no drug-related serious adverse events, and no cases of anaphylaxis or meningococcal infection.

INFORMATION ABOUT PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

Paroxysmal nocturnal hemoglobinuria (PNH) belongs to a group of fatal and rare disorders that occur when the complement system, a part of the immune system that helps clear microbes and damaged cells by attacking their cell membranes, is dysregulated. In patients with PNH, the proteins that normally protect their red blood cells are not present, leaving these denuded cells susceptible to complement attack, which results in their destruction (hemolysis). This leads to severe anemia, thromboembolism, gastrointestinal pain and dysfunction, fatigue, cardiac failure, pulmonary hypertension, renal impairment, and eventually, death.

INFORMATION ABOUT OMOPRUBART (CAN106)

Omoprubart (CAN106) is a novel, long-acting recombinant humanized monoclonal antibody that binds to and neutralizes C5, a key component of the complement system. By preventing the cleavage of C5 into C5a and C5b, Omoprubart is intended to prevent the C5b-dependent formation and activation of the membrane attack complex (MAC) on susceptible cell surfaces, which results in cell lysis (destruction). In the case of PNH, this is hemolysis, or the destruction of red blood cells. Omoprubart acts downstream of C3 in the complement pathway, preserving the generation of C3a and C3b, which are important for innate immunity.

The Company holds exclusive global development and commercialization rights to omoprubart for all indications. It is currently in development for PNH, as well as for other complement-mediated diseases that involve activation of the C5 protein.

INFORMATION ABOUT THE COMPANY

The Company is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare disease and rare oncology. It has a differentiated drug portfolio, with 4 approved drugs and a pipeline of 10 assets, targeting prevalent rare disease and rare oncology indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme.

There is no assurance that Omoprubart (CAN106) will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, June 26, 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. James Qun Xue as executive director; Dr. Kan Chen, Dr. Derek Paul Di Rocco and Mr. Edward Hu as non-executive directors; and Mr. James Arthur Geraghty, Dr. Richard James Gregory, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive directors.